GLP1R and metabolic syndrome: DPP-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP1Ras), GLP-1, and GIP dual receptor agonists, in addition to SGLT2 inhibitors, are among the newer drugs that are applied either independently or in conjunction with cholesterol-reducing drugs to achieve optimal outcomes for patients with dyslipidemia.